Ritholtz Wealth Management reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 42.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 14,351 shares of the biopharmaceutical company’s stock after selling 10,744 shares during the period. Ritholtz Wealth Management’s holdings in PTC Therapeutics were worth $930,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in shares of PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 151 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in shares of PTC Therapeutics by 1.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company’s stock valued at $1,120,000 after purchasing an additional 237 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of PTC Therapeutics by 8.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 244 shares during the period. State of Wyoming boosted its position in shares of PTC Therapeutics by 15.3% during the third quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 260 shares in the last quarter. Finally, Vise Technologies Inc. boosted its position in shares of PTC Therapeutics by 3.1% during the third quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 266 shares in the last quarter.
Insiders Place Their Bets
In related news, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the sale, the director directly owned 22,500 shares of the company’s stock, valued at approximately $1,466,100. This represents a 34.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the sale, the vice president owned 105,272 shares of the company’s stock, valued at approximately $6,754,251.52. This represents a 0.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 64,265 shares of company stock valued at $4,412,399. 5.30% of the stock is currently owned by corporate insiders.
PTC Therapeutics Trading Down 4.0%
PTCT stock opened at $60.97 on Tuesday. The firm has a 50 day moving average price of $63.95 and a 200-day moving average price of $70.20. PTC Therapeutics, Inc. has a 52-week low of $58.80 and a 52-week high of $90.87.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The company had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. During the same period in the previous year, the business posted $0.20 earnings per share. The firm’s quarterly revenue was up 69.6% compared to the same quarter last year. Research analysts predict that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.
PTC Therapeutics announced that its board has approved a share buyback plan on Tuesday, November 3rd that permits the company to buy back $500 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to buy up to 9.8% of its shares through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on PTCT. Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. UBS Group began coverage on PTC Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $90.00 price objective for the company. Cantor Fitzgerald boosted their target price on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. TD Cowen boosted their target price on shares of PTC Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, Morgan Stanley upped their target price on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.23.
Check Out Our Latest Analysis on PTCT
PTC Therapeutics Company Profile
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report).
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
